Protalix BioTherapeutics to Announce Q1 2024 Results on May 10, 2024

Protalix BioTherapeutics, Inc., a biopharmaceutical company located in Carmiel, Israel, is set to release its financial results for the first quarter of 2024 on May 10, 2024. The company, listed on the NYSE American under the ticker symbol PLX, focuses on developing, producing, and commercializing recombinant therapeutic proteins utilizing its unique ProCellEx® plant cell–based protein expression system. Alongside the financial results, Protalix will also provide a business and clinical update.

To discuss these financial results and recent corporate and regulatory developments, the management will be hosting a conference call for investors. This call is scheduled for Friday, May 10, 2024, at 8:30 a.m. Eastern Daylight Time (EDT). To participate in the call, investors can dial the toll-free number 1-877-423-9813 or the international number 1-201-689-8573. For those calling from Israel, the toll-free number is 1 809 406 247. Attendees can use the conference ID 13745800 when joining the call. Additionally, there is a Call me™ feature available that allows participants to enter their phone numbers on the platform, prompting the system to call them directly, thus avoiding the wait for an operator.

The company will also provide a webcast of the conference call, accessible through a company link and the webcast link provided. Participants are encouraged to access the call at least 15 minutes before the start time to register and download any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of Protalix's website.

Protalix BioTherapeutics is notable for its ProCellEx system, which is a plant cell-based protein expression system. This innovative technology was the first of its kind to receive approval from the U.S. Food and Drug Administration (FDA) for producing proteins using a plant cell-based suspension system. This system offers a novel method for industrial-scale development of recombinant proteins.

One of Protalix's significant achievements includes the development of taliglucerase alfa, a treatment for Gaucher disease. The worldwide rights for the development and commercialization of this product have been licensed to Pfizer Inc., except for in Brazil, where Protalix maintains full rights. Additionally, Elfabrio®, another product from Protalix, received approval from both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio.

Protalix's product pipeline features several proprietary versions of recombinant therapeutic proteins. These products target established pharmaceutical markets and include PRX-115, a plant cell-expressed recombinant PEGylated uricase intended for the treatment of uncontrolled gout, and PRX-119, a plant cell-expressed long-action DNase I aimed at treating NETs-related diseases.

The company continues to innovate within the biopharmaceutical industry, leveraging its proprietary technology to develop treatments that address unmet medical needs.